ClinicalTrials.gg
CompletedNCT03989492Updated Sep 23, 2025

Role of the Sympathetic Nervous System in Rosacea

An interventional study of systemic and local stressors in Rosacea, sponsored by Kristen Metzler-Wilson. Completed at 2 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Kristen Metzler-Wilson · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Rosacea is a common skin disorder which causes facial redness and inflammation in about 16 million Americans, from an unknown cause. Many triggers of rosacea symptoms are stressors that affect the sympathetic ("fight or flight") portion of the nervous system, and a recent pilot study suggests there is sympathetic dysfunction in rosacea. This project will benefit patients, clinicians, and basic scientists by increasing our understanding of sympathetic nervous system involvement in rosacea symptoms in order to develop improved treatments for patients with rosacea.

02

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • autonomic nervous system
  • skin blood flow
  • skin sympathetic nerve activity
03

In context

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

This study's enrollment of 40 is below the median of 61 across 200 interventional studies indexed under Rosacea.

Browse Rosacea studies →

Lead sponsor

This is the only study on the registry with Kristen Metzler-Wilson as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Otherwise healthy males and non-pregnant/non-lactating females with mild to moderate erythematotelangiectactic rosacea, as well as age-sex matched healthy control subjects.

Exclusion criteria

Exclusion Criteria:

  • Neurological, cardiovascular, respiratory, metabolic, muscular, or other dermatological disorders
  • Current history of alcohol and/or drug abuse
  • Known allergies or to medications/drugs that are used in the protocol
  • Current smoking or regular smoking within the last 2 years
  • > 35 kg/m2
  • Medications or supplements which are known to affect neural, cardiovascular, or muscular responses
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Autonomic responses to stressors

    Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.

    Other: systemic and local stressors

Interventions

  • Othersystemic and local stressors

    Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.

06

What researchers measure

Primary outcomes

  1. Skin blood flow

    laser Doppler flowmetry

    Time frame: Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.

  2. Skin sympathetic nerve activity

    microneurography

    Time frame: Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.

07

Study locations

2 sites
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kentucky
    Lexington, Kentucky 40506, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Aug 2020, 14 months.

Of 42 interventional studies with no phase under Rosacea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 18, 2019
StartActual
May 24, 2019
Primary completionActual
Aug 6, 2020
CompletionActual
Aug 6, 2020
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03989492
Lead sponsor
Kristen Metzler-Wilson
Responsible party
Kristen Metzler-Wilson (Associate Professor, University of Kentucky) — Sponsor-investigator
First posted
Jun 18, 2019
Start date
May 24, 2019
Primary completion
Aug 6, 2020
Completion
Aug 6, 2020
Last update
Sep 23, 2025

Study contacts

Kristen Metzler-Wilson, PT, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion